Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosfomycin+metronidazole+molgramostim - Reponex Pharmaceuticals

Next Previous
Drug Profile

Fosfomycin+metronidazole+molgramostim - Reponex Pharmaceuticals

Alternative Names: RNX-011

Latest Information Update: 24 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Reponex Pharmaceuticals
  • Class Anti-infectives; Anti-inflammatories; Antibacterials; Antibronchitics; Antifibrotics; Antiprotozoals; Chemoprotectants; Epoxy compounds; Nitroimidazoles; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Radiosensitisers; Recombinant proteins; Skin disorder therapies; Small molecules
  • Mechanism of Action Cell wall inhibitors; DNA synthesis inhibitors; Granulocyte macrophage colony stimulating factor replacements; Peptidoglycan inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Peritonitis

Most Recent Events

  • 14 Aug 2026 Reponex Pharmaceuticals plans enrolment of the first patient in clinical study of RNX 011 in late 2026
  • 14 Oct 2022 Fosfomycin+metronidazole+molgramostim is still in phase II trials for peritonitis in Denmark (Reponex Pharmaceuticals, October 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top